Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Passage Bio, Inc. - Common Stock (NQ:PASG)

0.4291 -0.0209 (-4.64%)
Streaming Delayed Price Updated: 1:07 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Passage Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 33 stocks hit new 52-week lows. 
Via Benzinga
Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
From Passage Bio
Via GlobeNewswire
Recap: Passage Bio Q1 Earnings
Via Benzinga
Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio's Earnings: A Preview
Via Benzinga
Expert Ratings for Passage Bio
Via Benzinga
Passage Bio Stock Jumps After Gene Therapy Study In Lysosomal Storage Disorder
Via Benzinga
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Passage Bio
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 89 stocks made new 52-week lows. 
Via Benzinga
Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
From Passage Bio
Via GlobeNewswire
Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Cowen 43rd Annual Health Care Conference
From Passage Bio
Via GlobeNewswire
Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023
From Passage Bio
Via GlobeNewswire
Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
From Passage Bio
Via GlobeNewswire
Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Passage Bio
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study
From Passage Bio
Via GlobeNewswire
Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Passage Bio
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
Upgrades 
Via Benzinga
Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day
From Passage Bio
Via GlobeNewswire
Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer
From Passage Bio
Via GlobeNewswire
Newman Ferrara LLP Announces Corporate Governance Investigations of Passage Bio, Inc. (PASG)
From Newman Ferrara LLP
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
  
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.